Treatment with Tyvaso (treprostinil) outperformed a placebo at preserving lung function and preventing clinical worsening — meaning, it led to gains beyond temporary symptom changes — among people with idiopathic pulmonary fibrosis (IPF) in the now-completed global TETON-2 clinical trial. United Therapeutics, Tyvaso’s developer and the study’s sponsor,…